for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-Hikma Pharmaceuticals FY Operating Profit Rose 33% To $493 Mln

Feb 27 (Reuters) - Hikma Pharmaceuticals PLC:

* FY OPERATING PROFIT ROSE 33 PERCENT TO 493 MILLION USD

* FY REVENUE 2.207 BILLION USD

* HIKMA PHARMACEUTICAL - FINAL RESULTS

* FY GROUP CORE REVENUE OF $2,203 MILLION, UP 6%

* FY GROUP CORE OPERATING PROFIT OF $508 MILLION, UP 10%

* FULL YEAR DIVIDEND OF 44 CENTS PER SHARE, UP FROM 38 CENTS PER SHARE

* FY INJECTABLES CORE REVENUE UP 7% DRIVEN BY STRONG DEMAND FOR OUR BROAD PORTFOLIO AND RECENT LAUNCHES

* 108 NEW PRODUCTS LAUNCHED ACROSS ALL MARKETS IN 2019, EXPANDING GLOBAL PRODUCT PORTFOLIO

* IN 2020, WE EXPECT INJECTABLES REVENUE TO GROW IN LOW TO MID-SINGLE DIGITS

* IN 2020, WE EXPECT GENERICS REVENUE TO BE IN RANGE OF $700 MILLION TO $750 MILLION

* EXPECT BRANDED REVENUE TO GROW IN MID-SINGLE DIGITS IN CONSTANT CURRENCY IN 2020.

* DO NOT CURRENTLY ANTICIPATE ANY MATERIAL IMPACT FROM RECENT OUTBREAK OF CORONAVIRUS DISEASE

* DO NOT HAVE EXTENSIVE OPERATIONS OR MANUFACTURING IN CHINA, NOR ARE WE DIRECTLY DEPENDENT ON CHINESE-MANUFACTURED GOODS OR SERVICES Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up